Last week, we participated in Medlab Middle East 2025, one of the world’s most prestigious exhibitions in the field of laboratory technologies, held in Dubai. This significant event provided us with the opportunity to connect with leading companies in the industry and establish new collaborations.
Medlab Middle East stands out as a platform that hosts hundreds of exhibitors and thousands of visitors every year, showcasing innovative diagnostic and laboratory technologies. As SHD, we received great interest throughout the exhibition with our products and solutions and had the chance to experience the global recognition of our brand once again.
During the event, we held productive meetings with distributors from various countries. As a result of these discussions, we took important steps towards expanding our global distribution network by forming new business partnerships. This presents a great opportunity for us to reach more customers worldwide and share our innovations in laboratory technology.
As SHD, we remain committed to making our innovative and reliable rapid diagnostic tests accessible to a broader geography. The connections and experiences gained at Medlab Middle East 2025 will continue to be a crucial part of our growth journey.
We extend our gratitude to all our partners who visited us and collaborated with us at the event. In the coming period, we will continue to strengthen our partnerships and solidify our position in the industry.
As Deniz Biochemistry, we are delighted to announce a significant partnership between our SHD brand and SEROCON R&D Biotechnology, a leader in innovative solutions within the biotechnology sector. This collaboration marks a major step toward developing technologies that add value to the industry and expanding our presence in the global market.
SEROCON stands out in the biotechnology field with its innovative quality control solutions that enhance precision and efficiency in laboratory processes. Its high-precision immunoassay and biochemistry tests, scientific consultancy, and R&D activities make it a distinguished name in the industry.
SHD Test, on the other hand, focuses on reliability in testing and analysis processes, offering innovative solutions in the medical and biochemical fields. With our innovative approach and robust infrastructure, we aim to meet the industry’s needs in the best possible way.
Working Together for Greater Goals
We are taking a big step forward! As Deniz Biochemistry, under our SHD brand, we are proud to collaborate with SEROCON R&D Biotechnology. This partnership will enable us to develop innovative solutions in laboratory technologies and lay the foundation for new growth in the global market. We will continue to work together for science and R&D!
Emergency departments are among the busiest and most critical areas of a hospital. Accurate and swift diagnosis is vital for saving patients’ lives. Cardiovascular diseases are one of the most common conditions seen in emergency departments, where precise diagnosis is crucial. At this point, the hs-cTnI (high-sensitivity cardiac troponin I) test offers groundbreaking innovation. So, how does this technology make a difference in emergency care?
Rapid Diagnostic Capability
In cases of heart attacks or other cardiac conditions, time is a critical factor. The hs-cTnI test enables early diagnosis by accurately measuring Troponin I protein levels. This fast turnaround time in emergency departments helps reduce workload and ensures that critical patients can begin treatment promptly.
Portable and Practical Use
Emergency departments are dynamic, often crowded environments where quick actions are essential. The hs-cTnI devices developed by SHD Test are portable and compact, perfectly suited for such settings. They can be easily moved to different units and used effectively in high-demand areas.
High Sensitivity and Low False-Negative Rates
The hs-cTnI test accurately detects cardiac muscle damage by measuring Troponin I levels, a reliable biomarker. This reduces false-negative rates significantly, even in less apparent cases. This capability ensures that even low-risk patients are assessed effectively.
Faster and Informed Decisions in Patient Management
The quick and accurate results provided by the hs-cTnI test enable emergency staff to make more informed decisions. This improves patient satisfaction and optimizes patient management processes. For instance, in suspected heart attack cases, unnecessary invasive procedures can be avoided, or urgent interventions can be initiated more quickly.
Advantages in Mobile Healthcare
In emergencies, the hs-cTnI test’s compact and efficient design allows it to be used on mobile healthcare platforms. This is particularly advantageous in ambulances or disaster areas, providing critical assistance and saving time.
Investing in the Future
The hs-cTnI test not only enhances current diagnostic methods but also lays the groundwork for future healthcare technologies. This technology, which leads the trends in personalized medicine and portable diagnostic devices (POCT), contributes to setting new standards in emergency departments and the healthcare industry at large.
Conclusion
Emergency departments need innovative technologies that enable quick and accurate decision-making, and the hs-cTnI test meets this need exceptionally well. With features like rapid results, portability, and high sensitivity, the widespread use of this test in emergency departments will improve the quality of patient care and provide life-saving solutions. For more information about SHD Test’s innovative technology and collaboration opportunities, please contact us.
The healthcare sector is undergoing rapid transformations driven by technological advancements. Especially in clinical laboratories, the need to provide faster and more accurate services to patients has made the development of next-generation devices increasingly important. Among INNOVIQURE’s standout devices, INNOVIQURE Nexus has previously showcased the remarkable impact of CLIA (Chemiluminescent Immunoassay) technology on healthcare. Now, another solution designed to address the pursuit of versatility and efficiency, INNOVIQURE Spectrum, is making significant contributions to laboratory environments.
Advanced Technology with a Broad Range of Parameters INNOVIQURE Spectrum offers the capability to perform tests across a wide range of applications, from blood disorders and thyroid problems to infectious diseases and tumor markers.
Anemia Tests: Enables precise measurement of biomarkers such as EPO, Ferritin, Folate, and Vitamin B12. Thyroid and Hormonal Balance: Provides accuracy in detecting parameters like Anti-TPO, Anti-Tg, and Free T3/T4. Tumor Markers: Analyzes markers such as CA 125 and CA 19-9 swiftly and accurately. This broad range enables laboratories to address diverse patient needs with a single device.
Design That Highlights Efficiency Spectrum is designed to deliver a user-friendly experience. Its 15-inch touchscreen and real-time consumable management minimize the time spent operating the device.
A notable feature is its 60 sample positions and STAT channel for urgent samples, ensuring uninterrupted and efficient operation even in high-demand laboratory settings.
Patient-Centric and Flexible Solutions Spectrum not only enhances laboratory efficiency but is also developed with a patient-centered approach. With fast test times (first result within ≤ 12 minutes) and multiple mode options (e.g., batch, random, STAT), it provides flexibility for various scenarios.
Moreover, the precision of CLIA technology combined with Spectrum’s advanced magnetic field design improves washing efficiency, enhancing confidence in the accuracy of tests.
INNOVIQURE: A Solution for Every Need Nexus and Spectrum represent different examples of INNOVIQURE’s expertise in healthcare technologies. Both devices have the potential to redefine the working standards of laboratories.
Discover INNOVIQURE SPECTRUM and redefine your laboratory’s efficiency, versatility, and patient satisfaction.
Contact us to bring the INNOVIQURE SPECTRUM advantage to your laboratory: [email protected]
Clinical laboratories are of critical importance in the medical field for accurate diagnosis and treatment. Today, the increasing number of patients and complex test demands have highlighted the need for speed, precision, and efficiency in laboratories. At this point, CLIA (Chemiluminescent Immunoassay) technology offers solutions that elevate laboratory performance to the next level. Innovative devices like INNOVIQURE NEXUS maximize the potential of this technology, making a significant impact in the industry.
What is CLIA Technology and Why is It Important?
CLIA technology is used in medical diagnostic tests, particularly for detecting biomarkers at low levels. This technology is based on measuring the light emitted as a result of a chemical reaction and stands out with the following advantages:
Sensitivity: The ability to detect even low concentrations of biomarkers.
Fast Results: Reliable test outcomes in a short period of time.
Versatility: The capacity to analyze various types of biomarkers.
These features enable laboratories to work more effectively and make quicker decisions in patient care.
INNOVIQURE NEXUS: Integration of CLIA Technology
INNOVIQURE NEXUS is one of the most efficient solutions utilizing CLIA technology. This innovative device has numerous features that facilitate laboratory workflows:
Compact Design: Weighing less than 38 kg, it is ideal for use in various settings.
User-Friendly Interface: Its touchscreen and simple control panel make it easy to operate.
High Capacity: Offers 30 sample and 10 reagent positions with 24-hour uninterrupted cooling and storage.
Smart Functions: Optimized alarm classification and compatibility with all Shine series analyzers’ reagents and consumables.
Accelerating Transformation in Laboratories
The fast, precise, and efficient performance offered by INNOVIQURE NEXUS redefines workflows in clinical laboratories. Its user-friendly interface allows laboratory staff to operate the device with ease and conduct tests with fewer errors. Additionally, the STAT channel enables much faster analysis of urgent samples.
A Step Towards the Future
The rapid advancement in medical technologies is making laboratory processes more efficient, and innovative devices like INNOVIQURE NEXUS are leading this transformation. Supported by the features of CLIA technology, this device provides a versatile solution for the present and future of laboratories.
Contact us to bring the INNOVIQURE NEXUS advantage to your laboratory: [email protected]
A major step forward in the early diagnosis of cardiovascular diseases: The high-sensitivity cardiac troponin I (hs-cTnI) test is revolutionising this field. SHD Test is pioneering this innovation by contributing not only to clinical results but also to academic research.
Clinical Accuracy and Reliability Troponin I protein is one of the most reliable biomarkers for detecting cardiac muscle damage. SHD Test’s hs-cTnI solution is accurate even at very low levels of 5 pg/ml. This enables early diagnosis as well as rapid detection of even less obvious cases. This high accuracy reduces false negative rates, especially in low-risk patients.
New Approaches in Diagnostic Technology The devices offered by SHD Test stand out with their high sensitivity as well as their portability and fast result capability. These features are particularly suitable for use in intensive care units, emergency services and mobile health platforms. The widespread use of high-sensitivity testing ensures more consistent clinical results and helps to make faster and more informed decisions in patient management.
Scientific Collaborations and Expanding Opportunities SHD Test aims to support innovative projects in the academic world. To this end, it offers hs-cTnI tests free of charge for use in research projects. This enables the development of new diagnostic protocols and independent validation of existing approaches. Thus, while contributing to the academic literature, gaps in clinical practice are also filled.
Personalised Medicine and POCT Trends In the healthcare sector, personalised medicine and portable diagnostic devices (POCT) are becoming increasingly important. hs-cTnI tests epitomise this trend, increasing patient satisfaction and improving the efficiency of healthcare systems. SHD Test’s technology not only meets these demands, but also contributes to the establishment of new diagnostic standards.
Steps for the Future The hs-cTnI test not only improves current diagnostic methods, but also lays the foundation for future healthcare innovations. We invite the academic and clinical communities to explore and develop these innovations. Please contact us for further information and collaboration opportunities.
In the rapidly evolving world of healthcare, timely and accurate diagnostics have always been at the forefront of better patient outcomes. One of the latest breakthroughs in this field comes from implementing high-sensitivity cardiac troponin I (hs-cTnI) tests on point-of-care testing (POCT) devices. This innovation promises to revolutionize emergency diagnostics and mobile healthcare, setting a new standard for rapid and reliable patient care.
High-Sensitivity, Rapid Diagnostics: A Game-Changer The hs-cTnI test is a cornerstone for diagnosing cardiac events, such as myocardial infarctions, and its integration into POCT devices is nothing short of revolutionary. Traditionally, such tests required centralized labs, delaying crucial decisions in emergency departments and mobile units. With our implementation, these barriers are eliminated:
Exceptional Sensitivity: Ensures reliable detection of cardiac biomarkers. Rapid Turnaround Times: Facilitates faster clinical decisions during critical moments. These improvements enable healthcare professionals to act swiftly and confidently, saving lives and enhancing the overall patient experience.
An Open Invitation to the Academic Community To further validate and expand the potential of this innovation, we’re inviting researchers and academics to join hands with us. Whether your expertise lies in comparative studies, independent evaluations, or clinical publications, we offer an unparalleled opportunity:
Free Access to Our Systems and Tests: Our POCT devices and hs-cTnI tests are available at no cost for qualified academic and clinical research. Support for High-Impact Research: Collaborate with us to generate groundbreaking findings for publication in leading journals. This partnership aims to create a robust body of evidence, setting new benchmarks in diagnostics and paving the way for widespread adoption of this life-saving technology.
The Impact of Collaboration By working together, we can redefine what’s possible in patient care. Academic contributions are crucial to ensuring the credibility and utility of this technology across diverse settings. From urban emergency rooms to remote mobile units, the potential applications are vast.
Through these collaborations, we aim to:
Validate the effectiveness of hs-cTnI in real-world scenarios. Encourage global standardization of POCT diagnostics. Inspire innovative approaches to healthcare challenges. Join Us in Shaping the Future of Healthcare This is more than a call for collaboration—it’s an opportunity to be part of a transformative journey. If you are passionate about advancing medical science and making a tangible impact on patient care, we want to hear from you. Let’s combine our expertise to create a future where diagnostics are faster, smarter, and more accessible to everyone.
Reach out to us today for more information about this initiative. Together, we can drive innovation and make a lasting difference in healthcare worldwide.
At this year’s MEDICA 2024, we’re thrilled to present some groundbreaking updates and innovations, capturing the attention of global audiences and healthcare professionals alike. Held annually, MEDICA is a prime platform for leading industry players, innovators, and visionaries to exhibit cutting-edge advancements in healthcare, diagnostics, and technology. As a proud participant, we’re excited to unveil our newest developments, including our CLIA test production and the region’s first high-sensitivity point-of-care testing (POCT) device for hs-cTnI. Let’s dive into the highlights of our participation and explore what these advancements mean for healthcare providers and patients worldwide.
Expanding CLIA Test Production: Precision and Quality Recognized Internationally Our CLIA test production has seen a surge of interest, attracting customers from numerous countries and reinforcing our dedication to quality and precision in diagnostics. Our comprehensive CLIA test panels cover a wide range of diagnostic needs, empowering healthcare professionals with reliable tools to make accurate and timely decisions. The attention we’re receiving at MEDICA 2024 underscores the global need for accessible, high-quality diagnostic tests, and we’re committed to meeting this demand through continuous innovation and rigorous quality standards.
By bringing our CLIA production to the global stage, we aim to foster partnerships that expand the accessibility and impact of our products. As we engage with a diverse network of industry professionals, we’re eager to collaborate, exchange knowledge, and explore new markets. Our commitment to quality resonates with healthcare providers looking for reliable and efficient diagnostic solutions, and we’re proud to represent this standard on an international platform.
Join Us at Hall 1, Stand F10: Discover Our Innovations Firsthand Our booth at Hall 1, Stand F10, offers an immersive experience for visitors interested in our latest diagnostic solutions. Here, attendees can get an up-close look at our advanced CLIA panels and learn about the features and benefits of each test. We’re also offering on-site demonstrations to showcase the ease of use, accuracy, and reliability of our systems.
We understand that seeing our products in action is essential for prospective partners and healthcare providers. By offering demo requests, we invite you to explore our solutions in detail and discuss how our innovations can address specific diagnostic needs. MEDICA is the ideal venue for connecting with industry peers and exploring potential collaborations, and we look forward to meaningful conversations that could lead to groundbreaking partnerships.
A Milestone in Diagnostic Innovation: The First Locally Produced hs-cTnI POCT Device One of the most exciting highlights of our showcase is our newly developed POCT device, designed specifically for high-sensitivity cardiac troponin I (hs-cTnI) testing. This groundbreaking system is the first of its kind produced locally, representing a significant milestone in accessible and efficient cardiac diagnostics. High-sensitivity hs-cTnI testing plays a crucial role in the early diagnosis and management of cardiac events, providing healthcare professionals with a valuable tool to improve patient outcomes.
Our POCT device enables rapid and reliable hs-cTnI measurements, making it an invaluable asset in emergency care and routine clinical settings. As demand for high-sensitivity diagnostic solutions grows, we’re proud to offer a locally manufactured system that meets rigorous quality standards. This innovation not only enhances diagnostic capabilities for healthcare providers but also supports our mission to elevate patient care through cutting-edge technology.
Driving Global Partnerships and Elevating Patient Care As we present our innovations at MEDICA 2024, we’re committed to building and strengthening partnerships with healthcare providers, distributors, and institutions worldwide. Our solutions, designed to meet the evolving needs of modern healthcare, offer a unique opportunity for collaboration in advancing diagnostic technology. By connecting with industry leaders and discussing specific diagnostic needs, we aim to create impactful solutions that elevate patient care across borders.
Our participation at MEDICA 2024 is more than an exhibition; it’s a celebration of our dedication to quality, innovation, and global accessibility. We invite you to join us at Hall 1, Stand F10 to discover how our CLIA test production and high-sensitivity POCT device for hs-cTnI testing can enhance diagnostic precision and improve patient outcomes. Together, let’s explore new possibilities for collaboration and innovation in healthcare.